Abbott’s Bluetooth connected cardioverter defibrillator and cardiac resynchronization therapy defibrillator, part of the Gallant product line, scored FDA clearance this morning.
Patients using the technology can connect it to a smartphone app, called MyMerlinPulse, which will let both patients and providers see transmission history and device performance. The app is also designed to nudge patients to set up their next doctor’s appointment. Doctors are able to tap into the app in order to remotely monitor patients and detect any potentially problematic events.
This FDA designation includes the MyMerlinPulse App and the software to program the Gallant family of devices on the programmer, according to a company spokesperson.
WHY IT MATTERS...
Heart conditions are common in the US. In fact, atrial fibrillation impacts between 2.7 million and 6.1 million people in the United States, according to the CDC. The company is pitching this product as another way for doctors to monitor their patients' heart conditions remotely.
"The ability for patients to stay connected to their doctors via their implanted device and a smartphone app has the potential to change how healthcare providers and patients communicate with each other," Dr. Raffaele Corbisiero, director of electrophysiology and pacing at Deborah Heart and Lung Center, Browns Mills, said in a press statement. "The FDA's approval of Abbott's Gallant devices enables doctors to provide a more collaborative approach to treatment plans and the increased bond between a patient and provider will lead to better outcomes for all."
For more information click the link below;
